78 % ( 95 % CI 69-87 ) of patients in the rituximab induction group did not need treatment at 3 years , which was significantly more than in the watchful waiting group ( HR 035 , 95 % CI 022-056 ; p < 00001 ) , but no different compared with the maintenance rituximab group ( 075 , 041-134 ; p = 033 ) .